Perioperative HALP and Surgical Outcomes

NCT07761975 | Completed

• 1 other identifier: 2026-206
• Study Type: observational
• Target: 131
• Locations: 1 country
• Sites: 1

Brief Summary

Esophagectomy is associated with substantial postoperative morbidity despite advances in perioperative care. The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score has been proposed as a composite biomarker reflecting nutritional, inflammatory, and immune status; however, its perioperative behavior and clinical significance after esophagectomy remain unclear. This retrospective cohort study evaluates perioperative changes in HALP and examines the associations of preoperative, postoperative day 1, and postoperative day 7 HALP measurements with postoperative complications, including overall and major complications, anastomotic leakage, ICU readmission, and length of hospital stay. The study aims to clarify the potential role of perioperative HALP as a marker of postoperative recovery and adverse clinical outcomes following esophagectomy.

Conditions

Esophagectomy; HALP Score; Perioperative Biomarkers; Postoperative Complications; Perioperative Risk Assessment

Keywords

Esophagectomy; HALP score; Perioperative biomarkers; Postoperative complications; Perioperative Risk Assessment

Outcome Measures

Primary Outcomes (1)

• Incidence of postoperative complications

  Incidence and severity of postoperative complications following esophagectomy, classified according to the Clavien-Dindo classification. HALP scores were measured at baseline (preoperatively) and on postoperative days 1 and 7 and were evaluated as predictors of postoperative complications. Postoperative complications were assessed from the day of surgery through hospital discharge.

  Baseline (preoperative), postoperative day 1, and postoperative day 7 for HALP measurements; Postoperative complications - from the day of surgery to hospital discharge, with follow-up extending up to 101 days in the patient with the longest stay

Secondary Outcomes (3)

• Incidence of major postoperative complications (Clavien-Dindo grade III or higher)

  Baseline (preoperative), postoperative day 1, and postoperative day 7 for HALP measurements; Postoperative complications - from the day of surgery to hospital discharge, with follow-up extending up to 101 days in the patient with the longest stay

• Incidence of unplanned intensive care unit (ICU) readmission

  From the day of surgery to hospital discharge, with follow-up extending up to 101 days in the patient with the longest stay

• Perioperative changes in HALP score

  Baseline (preoperative), postoperative day 1, and postoperative day 7 for HALP measurements

Study Arms (1)

Patients Undergoing Esophagectomy

Adult patients who underwent elective esophagectomy for esophageal cancer at a single tertiary referral center between June 2020 and March 2025. Patients with available perioperative laboratory measurements required for calculation of the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score before surgery and on postoperative days 1 and 7 were included in the retrospective cohort.

Other: Perioperative HALP Score Assessment

Interventions

Perioperative HALP Score Assessment OTHER

Assessment of the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score using routinely collected laboratory measurements obtained preoperatively and on postoperative days 1 and 7. No intervention or treatment was assigned as part of the study.

Patients Undergoing Esophagectomy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This retrospective cohort study included adult patients who underwent elective esophagectomy with curative intent for histologically confirmed esophageal cancer at a single tertiary referral center between June 2020 and March 2025. Patients with available perioperative laboratory data for calculation of the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score before surgery and on postoperative days 1 and 7 were included.

You may qualify if:

• Adults aged 18 years or older.
• Histologically confirmed esophageal cancer.
• Underwent elective esophagectomy with curative intent between June 2020 and March 2025.
• Available laboratory data for calculation of the Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score preoperatively and on postoperative days 1 and 7.
• Complete clinical data regarding postoperative outcomes

You may not qualify if:

• Age younger than 18 years.
• Benign esophageal disease or surgery performed for indications other than esophageal cancer.
• Emergency esophagectomy.
• Missing laboratory data required for calculation of the HALP score at any of the predefined time points (preoperative, postoperative day 1, or postoperative day 7).
• Incomplete clinical or follow-up data regarding postoperative outcomes.

Sponsors & Collaborators

• Istanbul Saglik Bilimleri University: lead

Study Sites (1)

Basaksehir Cam and Sakura City Hospital

Istanbul, Istanbul, 34480, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Postoperative Complications

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Hürü Ceren Gökduman, MD

  Basaksehir Cam ve Sakura State Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assoc. Prof.

Study Record Dates

• First Submitted: July 23, 2026
• First Posted: August 13, 2026
• Study Start: June 10, 2026
• Primary Completion: July 15, 2026
• Study Completion: July 22, 2026
• Last Updated: August 13, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)